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generally negative perception of RO. The Belgian Radiation 
Oncology Awareness Organisation (BRAVO) is a collaborative 
platform of medical practitioners and industrial partners, 
created to evaluate and where required increase knowledge 
concerning radiation oncology by the general population, 
healthcare workers and policy makers. As a first step it was 
decided to assess the awareness of the general population. 
Materials and Methods: Between March and June 2014, data 
for this survey was collected during face-to-face streets 
interviews in all Belgian provinces. Questionnaires included 
fourteen questions articulated around four major themes: 
general awareness, efficacy, security and comfort, and 
innovation. Where required, open questions were used to 
avoid inducing answers. For most questions more then one 
answer was registered, and in that case the order of answers 
was noted. 
Results: Participants (n=746) were well balanced for gender 
and geographical distribution was homogeneous. Age 
distribution showed that a majority of participants was 
younger than 40 years (57%). We report here on a subset of 
questions. 
When looking at different therapeutic modalities for cancer, 
59 % of participants spontaneously cited RO as an option. 
However, when asked about the modality that offers the best 
cure chances, the RO score was well below surgery and 
chemotherapy with 13, 40 and 26% of positive answers 
respectively. Knowledge on treatment of cancer is mainly 
based on experiences in the personal environment (56%) and 
TV (37%), followed by written press (24%); the internet, 
school and hospitals being cited as other sources of 
information. 
On the safety issue, 33.8% of responders considered RO as an 
‘unsafe’ technique compared to 28.1% for whom it was 
‘safe’. RO was perceived as safe as chemotherapy, but less 
safe than surgery. Discussing potential side effects, 
participants seemed confused and cited problems induced by 
chemotherapy: 'hair loss' was more frequently mentioned 
(21%) than 'skin burns' (12%), with 36% having no idea about 
any radiotherapy toxicity. 
Lastly, asked about the treatment modality considered most 
innovative, radiotherapy came first (35%) before 
chemotherapy (31%) and surgery (16%). 
Conclusions: Knowledge of RO in Belgian general population 
is relatively poor and confusion with other treatment 
modalities exists. RT is not readily recognized as an effective 
treatment option and seems associated with insecurity. There 
is a clear need for future educational efforts targeted to the 
general population.  
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Purpose/Objective: Prospective evaluation of psychological 
variables including cut-off scores of psychological tests in 
aspect of outcome in  
head and neck cancer (HNC) patients treated by radiation 
alone, concurrent and sequential chemo-radiation. 
Materials and Methods: Eighty patients (women - 28%, men - 
72%, stage I/II - 17%, III - 15%, IV - 68%) were treated with by 
Accelerated Radiotherapy Alone (ARA - 60%) or Concurrent 
Chemo-Radiation (CCR - 40%) in some cases preceded by 
induction chemotherapy. The patients completed modified 
Hospital Anxiety and Depression Scale (HADS-M with 
additional aggression-irritability subscale), Distress 
Thermometer, Satisfaction with Life Scale, Visual–Analog 
Scales (VAS) of pain in HN area before (80 pts) and after (71 
pts) therapy. Clinical data, psychosocial and marital status of 
patients were included into the analysis as well.  
Results: Local control (LC) and overall survival (OS) rates at 3 
year follow-up were respectively 62% and 63%. At baseline, 
30% of patients were clinically depressed (15/42 or more 
points of general HADS score including depression and anxiety 
subscales). Overall HADS score was correlated with rates of 
3-year OS and LC, i.e. in patients with HADS <10p there were 
77% of LC and 73% of OS, but in HADS ≥10p there were 47% of 
LC and 54% of OS (p<0.021 and p<0.045, respectively). Fifty 
seven percent of patients reported baseline pain in HN area 
measured by VAS (42.5% - no pain, 27.5% - weak pain 1-3p, 
27.5% - moderate pain 4-6p, 2.5% - intense pain 7-10p). VAS 
score was correlated with rates of 3-year OS and LC, i.e. 
patients with moderate and intense pain of HN area (4-10p) 
had significantly lower LC and OS rates compare to patients 
with less pain (0-3p) – 29% and 32% versus 75% and 78%, 
respectively (p<0.00131, p<0.00033). Both HADS score and 
baseline VAS HN pain were not correlated with T and N stage, 
site of disease, age and sex. Baseline HADS score and HN pain 
intensity at baseline weakly correlated each other (R=0.24, 
p<0.05). Compared to the patients who had only CCR or ARA, 
induction chemotherapy group had 50% lower depression 
score after completing radiotherapy (p<0.05). Baseline C-
Reactive Protein level was related to increased depression 
and general higher HADS scores (R=0.31, p<0.05). Living 
alone without partner or family correlated with baseline HN 
pain (R=0.37, p<0.05) and stage of cancer (R=0.27, p<0.05). 
Conclusions: Baseline subclinical depressive symptomatology 
and elevated HN pain seem to play a significant role in the 
effectiveness of HNC radiation-related treatment, 
additionally to the other, well-known prognostic factors. 
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Ontologies can be used to increase data quality by describing 
the variables that are recorded in databases and the 
relationship between them. The definition of an ontology is 
“a formal description of the entities and the relationships 
between them for a given domain”. In radiation oncology, 
entities are classes like patients, diseases, CT-scans, 
radiotherapy treatments etc. and individuals like a specific 
MR scan or a specific treatment in a specific patient. 
Relationships can be simple such as specifying entities being 
sub classes, types, domains, ranges etc. of one another and 
data properties (e.g. dates) to more complex relationships 
such as a specific toxicity that occurred in a specific patient 
due to a specific radiotherapy treatment.  
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Ontologies set the rules for describing such things and are 
therefore often explained as formal frameworks for 
representing knowledge. Many (200+) biomedical ontologies 
exist and a comprehensive repository can be found at the 
Bioportal (http://bioportal.bioontology.org/). The Radiation 
Oncology Ontology can be found at the Bioportal and a new 
ontology that tries to describe the radiation oncology 
domain.  
Part of an ontology’s formal definition is the assignment of a 
code or identifier to each entity. With the advent of 
Semantic Web technology and specifically the Web Ontology 
Language (OWL) these identifiers take the form of the web 
standard Uniform Resource Identifiers. As an example in the 
NCI Thesaurus, Intensity-Modulated Radiation Therapy has 
the URI  
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1613
5.   
When people use the same ontology and thus the same URI to 
code things, the datasets they generate are much more 
interoperable and can thus more easily be shared compared 
to using one’s own terms and definitions to describe things. 
An ultimate goal of these efforts is to re-use clinical and 
research data in such a way that all radiation oncology 
becomes Linked Data, “a method of publishing structured 
data so that it can be interlinked and become more useful”.  
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“Omics” approaches, particularly genomics, have been part 
of the drive towards the need for “big-data” to allow for 
meaningful analyses of the effects of complex factors and 
their interactions. To achieve such data in a timely manner 
has led to the establishment of an ever increasing number of 
scientific consortia that allow for the rapid pooling of both 
biological samples and their associated meta-data. Such 
consortia normally involve multiple individual smaller studies 
across several countries and often continents. This in turn 
raises challenges for the approach to biobanking and for the 
equitable sharing of the combined resource. 
Two broad approaches to the biobanking have been adopted: 
1.      The individual study samples are sent and centrally 
pooled and analysed.  
2.      The samples are retained and analysed locally by the 
individual studies and the subsequent electronic data pooled. 
The first approach has the advantage of a more uniform 
approach to the analysis of the ensuing sample biobank but 
raises issues around appropriate documented material 
transfer arrangements. Such documentation is often not 
trivial and can run into difficulties in terms of the individual 
studies own legal and ethical restrictions on their wider use. 
It can also raise potential challenges to the storage and 
organisation of the samples to allow for subsequent efficient 
use in addition to issues around open and fair collaborative 
models of working that should allow for each contributing 
partner to have equitable access to the pooled resource. 
The second approach raises a different set of issues in terms 
of ensuring quality and consistency of analyses of the samples 
themselves across multiple labs and potentially different 
platforms. Furthermore, whilst allowing the individual studies 
seemingly greater retained “ownership” of the samples 
themselves the transfer of the ensuing data still raises the 
need for appropriate protocols for the ensuing controlled use 
of the pooled dataset itself. 
Both approaches thus have their inherent limitations and 
both models continue to be used across different consortia. 
We will demonstrate some of the issues raised in practice 
using examples from our experience of involvement in large 
scale consortia in cancer. Particular issues around the time 
taken to achieve the appropriate paperwork for pooling raise 
important considerations for the planning of further 
initiatives whilst issues around equitable access give rise to 
potential feelings of unfairness and reduced willingness to 
participate in further consortia initiatives. Appropriate 
biobanking practices necessary for any subsequent re-
sampling will also be considered. Such real and potentially 
imagined factors raise important issues going forwards with 
the “big data” agenda and could limit the most rapid and 
powerful integration of studies in the future.  
In conclusion important lessons learnt from early consortia 
building initiatives, which have largely been built based on 
common sense principles, need to be learnt and integrated 
with more rigorous formal management standards such as ISO 
9001, to maximise the utility and efficiency of large scale 
biobanks  going forwards. 
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Imaging data are increasingly used in radiotherapy. 
Functional imaging with FDG-PET is currently tested in 
several trials of dose painting. The versatility of MRI affords 
both anatomical and functional images: T2-weighted MRI 
provides anatomical detail with excellent soft-tissue 
contrast; diffusion-weighted MRI has potential as an early 
marker for response to treatment; dynamic contrast-
enhanced MRI reflects the properties of the microvasculature 
in tissue. A clear connection with hypoxia has been 
established in cervical cancer and its prognostic value is also 
suggested in head and neck cancer. Increasingly, these 
imaging techniques are therefore added to clinical trial 
protocols to guide decisions about target delineation and 
dose levels, but also to monitor treatment response. 
Traditionally, a qualitative interpretation of the data is given 
by the nuclear medicine physician or radiologist. This is 
sensitive to variations in imaging protocols influencing the 
appearance of the images. It also is subjective and relies 
strongly on observer experience. The use of quantitative, 
rather than qualitative data can be a solution to this 
problem. For PET, the Standard Uptake Value (SUV) has 
become the prevailing method to represent the data. Similar 
opportunities exist for MRI. T2-mapping combines anatomical 
information with quantitative information about the T2-value 
of the tissue. For diffusion-weighted imaging, the apparent 
diffusion coefficient (ADC) is a reproducible metric. For 
dynamic contrast-enhanced MRI, tracer kinetic modeling is 
used to extract quantitative data.  
Quantification thus holds the prospect to provide data that 
are consistent between institutes and types of scanners. 
However, the advancement in understanding the value of 
imaging methods is held back by a lack of consistency in 
methodology. Different methods for acquisition and analysis 
